Allspring Global Investments Holdings LLC Sells 4,612 Shares of Evolus, Inc. (NASDAQ:EOLS)

Allspring Global Investments Holdings LLC decreased its position in shares of Evolus, Inc. (NASDAQ:EOLS) by 37.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 7,733 shares of the company’s stock after selling 4,612 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Evolus were worth $81,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in EOLS. Vanguard Group Inc. lifted its position in Evolus by 37.9% during the 3rd quarter. Vanguard Group Inc. now owns 2,698,647 shares of the company’s stock valued at $24,666,000 after acquiring an additional 741,451 shares during the period. Stonepine Capital Management LLC increased its stake in shares of Evolus by 14.9% during the third quarter. Stonepine Capital Management LLC now owns 5,179,004 shares of the company’s stock valued at $47,336,000 after purchasing an additional 672,807 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of Evolus by 61.7% during the third quarter. Rice Hall James & Associates LLC now owns 1,105,159 shares of the company’s stock valued at $10,101,000 after purchasing an additional 421,890 shares during the last quarter. Walleye Capital LLC boosted its position in shares of Evolus by 650.1% in the 3rd quarter. Walleye Capital LLC now owns 293,084 shares of the company’s stock worth $2,679,000 after purchasing an additional 254,013 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in shares of Evolus in the 3rd quarter worth approximately $1,200,000. Institutional investors own 90.69% of the company’s stock.

Insider Activity

In other news, insider David Moatazedi sold 7,706 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $13.08, for a total transaction of $100,794.48. Following the completion of the transaction, the insider now directly owns 792,416 shares of the company’s stock, valued at $10,364,801.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Sandra Beaver sold 5,672 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the transaction, the chief financial officer now directly owns 154,201 shares of the company’s stock, valued at approximately $2,146,477.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Moatazedi sold 7,706 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $13.08, for a total value of $100,794.48. Following the completion of the transaction, the insider now owns 792,416 shares in the company, valued at $10,364,801.28. The disclosure for this sale can be found here. Insiders have sold a total of 49,038 shares of company stock valued at $674,232 in the last 90 days. 5.40% of the stock is currently owned by insiders.

Evolus Trading Up 2.4 %

Shares of EOLS opened at $11.71 on Tuesday. The company has a market cap of $678.48 million, a price-to-earnings ratio of -10.49 and a beta of 1.45. The business’s fifty day simple moving average is $13.39 and its two-hundred day simple moving average is $11.29. Evolus, Inc. has a 12 month low of $7.07 and a 12 month high of $15.43.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The company had revenue of $61.00 million during the quarter, compared to the consensus estimate of $61.14 million. As a group, research analysts forecast that Evolus, Inc. will post -0.51 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on EOLS. Barclays upgraded Evolus from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $10.00 to $16.00 in a research note on Monday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Friday, March 1st. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, April 10th.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.